Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
J Atheroscler Thromb ; 31(2): 122-134, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-37704431

ABSTRACT

AIM: Omega-3 fatty acids have emerged as a new option for controlling the residual risk for coronary artery disease (CAD) in the statin era. Eicosapentaenoic acid (EPA) is associated with reduced CAD risk in the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention trial, whereas the Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia trial that used the combination EPA/docosahexaenoic acid (DHA) has failed to derive any clinical benefit. These contradictory results raise important questions about whether investigating the antiatherosclerotic effect of omega-3 fatty acids could help to understand their significance for CAD-risk reduction. METHODS: The Attempts at Plaque Vulnerability Quantification with Magnetic Resonance Imaging Using Noncontrast T1-weighted Technic EPA/DHA study is a single-center, triple-arm, randomized, controlled, open-label trial used to investigate the effect of EPA/DHA on high-risk coronary plaques after 12 months of treatment, detected using cardiac magnetic resonance (CMR) in patients with CAD receiving statin therapy. Eligible patients were randomly assigned to no-treatment, 2-g/day, and 4-g/day EPA/DHA groups. The primary endpoint was the change in the plaque-to-myocardium signal intensity ratio (PMR) of coronary high-intensity plaques detected by CMR. Coronary plaque assessment using computed tomography angiography (CTA) was also investigated. RESULTS: Overall, 84 patients (mean age: 68.2 years, male: 85%) who achieved low-density lipoprotein cholesterol levels of <100 mg/dL were enrolled. The PMR was reduced in each group over 12 months. There were no significant differences in PMR changes among the three groups in the primary analysis or analysis including total lesions. The changes in CTA parameters, including indexes for detecting high-risk features, also did not differ. CONCLUSION: The EPA/DHA therapy of 2 or 4 g/day did not significantly improve the high-risk features of coronary atherosclerotic plaques evaluated using CMR under statin therapy.


Subject(s)
Coronary Artery Disease , Fatty Acids, Omega-3 , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Plaque, Atherosclerotic , Humans , Male , Aged , Plaque, Atherosclerotic/diagnostic imaging , Plaque, Atherosclerotic/drug therapy , Docosahexaenoic Acids , Eicosapentaenoic Acid , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/drug therapy , Fatty Acids, Omega-3/therapeutic use
2.
J Cardiol ; 76(1): 35-43, 2020 07.
Article in English | MEDLINE | ID: mdl-32389534

ABSTRACT

Dual antiplatelet therapy (DAPT) reduces the risk of ischemic events, including stent thrombosis, in patients undergoing percutaneous coronary intervention (PCI), while oral anticoagulants are superior to antiplatelet therapy for preventing thromboembolic events, including ischemic stroke, in patients with atrial fibrillation (AF). Reportedly, the AF population accounts for approximately 5 to 10% of patients undergoing PCI. From a theoretical viewpoint, combination therapy of DAPT and oral anticoagulation was previously recommended in patients with AF undergoing PCI. However, long-term triple therapy carries the risk of major bleeding. Recent clinical trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, and ENTRUST AF-PCI trials) demonstrated the advantage of dual therapy with an oral anticoagulant (warfarin or direct oral anticoagulant) plus an antiplatelet agent, which decreased the rate of major bleeding in the acute phase in AF patients who underwent PCI. These results affected guidelines, which now recommend that the duration of triple therapy should be limited, and dual therapy should be considered an alternative regimen when considering the bleeding risk. The current guidelines recommend monotherapy with an oral anticoagulant after 12 months of combination therapy, or in patients with AF and stable coronary artery diseases not requiring intervention. However, this approach has yet to be validated by randomized, controlled trials. Recently, the AFIRE trial demonstrated that rivaroxaban monotherapy was noninferior to dual therapy in terms of efficacy and superior in terms of safety in this population. Accumulating evidence demonstrates that there has been a paradigm shift in antithrombotic therapy to a "less is more" regimen. This article reviews current evidence and focuses on the optimal approach to antithrombotic treatment in patients with AF undergoing PCI in acute and chronic/stable phases.


Subject(s)
Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Coronary Artery Disease/drug therapy , Fibrinolytic Agents/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Administration, Oral , Drug Therapy, Combination , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Humans , Thrombosis/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL